Palvella Therapeutics, Inc. announced on June 29, 2026, that Matthew Pauls has been appointed to its Board of Directors. The board size has been increased from seven to eight members. Mr. Pauls' initial term as a Class I director will expire at the Company's 2027 Annual Meeting of Stockholders. He brings extensive experience from leadership roles in the biopharmaceutical industry, including his current position as CEO of Savara, Inc. Mr. Pauls will receive an annual retainer and was granted an option to purchase 6,000 shares of the Company's common stock, vesting over 36 months.